Recorrendo ao Instagram, o cantor Tony Carreira falou sobre um "enorme desafio", vivido com uma pessoa que lhe é bastante especial. É já no próximo dia 30 de dezembro que é lançado o videoclipe da ...
Emmy Award-winning journalist Tony Dokoupil has been named anchor of the "CBS Evening News," the network announced Wednesday. He begins his new role on Monday, Jan. 5, 2026, ushering in an ambitious ...
He replaces John Dickerson and Maurice DuBois in one of the most high-profile decisions of Bari Weiss’s early tenure as the network’s editor in chief. By Michael M. Grynbaum CBS News on Wednesday ...
With his new gig, Tony Dokoupil may be able to hit snooze on his early bird alarm clock. The Emmy Award-winning TV journalist and CBS News staple has been named the anchor of "CBS Evening News," CBS ...
SAN DIEGO Dec 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and ...
Novo Nordisk (NVO) appears undervalued relative to Big Pharma peers, especially given its superior long-term growth and profitability metrics outside of recent setbacks. NVO’s two-thirds market cap ...
Novo Nordisk A/S has acquired Zaltenibart, a Phase 2 MASP-3 inhibitor, for up to $2.1 billion, signaling strong conviction in its long-term potential. NVO shares have declined ~20% since October, now ...
Dec 2 (Reuters) - Wegovy maker Novo Nordisk (NOVOb.CO), opens new tab is planning to test its experimental obesity drug, CagriSema, in overweight children and adolescents, according to a U.S. registry ...
Semaglutide failed to demonstrate slowed Alzheimer’s progression in EVOKE/EVOKE+ preliminary results, though some biomarkers improved. Stock plunged intraday, then partly recovered; shares are down ...
Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two major trials last month that found an older drug similar to Ozempic had no effect in slowing ...
The government has just negotiated a significant price reduction for the diabetes and weight-loss treatment. The stock jumped following this news, signaling that it's not as bad as it seems at first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback